Towards Healthcare Research & Consulting
Lung Disease Therapeutics Market
Updated Date: 03 August 2026   |   Report Code: 5066
[email protected] +1 804-441-9344
Download Sample Order Now

Lung Disease Therapeutics Market Analysis, Demand and Growth Rate Forecast 2035

According to market projections, the lung disease therapeutics sector is expected to grow from USD 102.85 billion in 2026 to USD 175.25 billion by 2035, reflecting a CAGR of 6.1%. Lung disease therapeutics focus on treating conditions like asthma, COPD, pulmonary fibrosis, and infections. These treatments include inhalers, medications, oxygen therapy, and advanced options like biologics and gene therapy. The goal is to improve breathing, reduce symptoms, and enhance patients' quality of life.

Last Updated : 03 August 2026 Category: Therapeutic Area Insight Code: 5066 Format: PDF / PPT / Excel

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Lung Disease Therapeutics Market Assessment

  • Overview
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and Africa

North America Lung Disease Therapeutics Market Assessment

  • Overview
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Europe Lung Disease Therapeutics Market Assessment

  • Overview
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Asia-Pacific Lung Disease Therapeutics Market Assessment

  • Overview
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Latin America Lung Disease Therapeutics Market Assessment

  • Overview
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Middle East and Africa Lung Disease Therapeutics Market Assessment

  • Overview
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Company Profiles

  • Johnson & Johnson
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Allergan Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Merck & Co
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Novartis AG

Conclusion & Recommendations

FAQ's

Answer : Lung disease therapeutics market stands at USD 102.85 billion in 2026 and is expected to reach USD 175.25 billion by 2035, growing at a CAGR of 6.1% from 2026 to 2035.

Answer : Several factors contribute to the growth of the lung disease therapeutics market, including the increasing prevalence of lung diseases worldwide, rising aging population, growing awareness about respiratory health, technological advancements in diagnostics and treatment options, and the development of targeted therapies. Additionally, lifestyle changes, environmental factors, and the impact of air pollution also play a role in the increasing demand for lung disease therapeutics.

Answer : While the growth prospects may vary across different segments, chronic obstructive pulmonary disease (COPD) is expected to witness significant growth in the forecast period. COPD is a leading cause of morbidity and mortality globally, and the rising prevalence of smoking and environmental pollutants contributes to the increasing burden of COPD cases, driving the demand for effective therapeutics.
Any Questions

Meet the Team

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar